Facio presents FSHD drug discovery progress at the World Orphan Drug Congress

Facio Therapies will present its progress in facioscapulohumeral dystrophy (FSHD) drug discovery at the World Orphan Drug Congress Europe in Brussels, Belgium, on November 17th, 2016.

The World Orphan Drug Congress Europe provides a networking platform for all stakeholders in the rare disease industry, including pharma, biotechs, investors, payers, regulators, and patient advocates. In a Pitch & Partner session, Facio will present its mission to improve the lives of people with FSHD by developing a small molecule-based causal therapy, and showcase the latest results from its breakthrough drug discovery platform for FSHD. Facio’s  Pitch & Partner session will be held at the Sheraton Airport Hotel in Brussels, Belgium, on November 17th, 2016 at 14:05 (CET). Facio’s managing director, David Dasberg, will present.